

Technology Appraisals Committee D Interests Register

Topic: Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]

Publication Date: 12/07/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor David Meads	Committee member	Non-financial professional	University of Leeds has received funding from Takeda for research in an unrelated area.	N/A	20.12.2022	N/A	It was agreed his declaration would not prevent Professor Meads from participating in discussion on this appraisal
Dr Robert Hodgson and Professor Sofia	Committee members	Non-financial professional	Dr Hodgson and Professor Dias are part of the York EAG team who carried out this assessment for this appraisal	N/A	SD 15.12.2023 RH 04.01.2023	N/A	as a direct conflict Dr Hodgson and Professor Dias did not participate in discussions on this appraisal
Debra Montague	Patient expert	Indirect financial	ALK Positive UK has received funding from Takeda and Roche to hold a Patient Conference in the UK.	N/A	08.03.2022	N/A	It was agreed that her declaration would not prevent Debra from providing expert advice to the committee.
Dr Alastair Greystoke	Clinical expert	Financial	Dr Greystoke has received consultancy and speaker fees from Amgen, AstraZeneca, Boehringer	N/A	25.03.2022	N/A	It was agreed that his declaration would not prevent Dr Greystoke

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
			Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer and Roche for treatments in SCLC and NSCLC.				from providing expert advice to the committee.